Novartis announced that combining Pluvicto (lutetium-177 vipivotide tetraxetan) with standard care (ARPI + ADT) significantly improves PSA response in metastatic hormone-sensitive prostate cancer (mHSPC), reducing PSA progression risk by 58% compared to standard care alone. Data from the PSMAddition trial showed deeper and more durable PSA reductions at 12, 24, and 48 weeks, with a higher percentage of patients achieving very low PSA levels. Safety was consistent with previous studies, though grade ≥3 adverse events were slightly higher with Pluvicto. Regulatory submissions have been filed in the US, China, and Japan, with decisions expected in the second half of 2026, potentially redefining treatment standards for metastatic prostate cancer.
Biotechnology ETFs have surged in 2026, driven by advances in AI drug discovery and a wave of mergers and acquisitions. AI models are accelerating early-stage research, reducing costs, while large pharma companies are acquiring smaller firms to offse...
The iShares Core MSCI EAFE ETF has gained about 10.5% year to date and 24% over the past year, benefiting from a weaker U.S. dollar and strong holdings in European and Japanese megacaps like ASML and major pharma companies. The fund's performance is ...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
